These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 30196651)

  • 1. Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?
    Cho YK
    Clin Mol Hepatol; 2018 Sep; 24(3):299-301. PubMed ID: 30196651
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease.
    Sayari S; Neishaboori H; Jameshorani M
    Clin Mol Hepatol; 2018 Sep; 24(3):331-338. PubMed ID: 29890569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial.
    Mofidi F; Poustchi H; Yari Z; Nourinayyer B; Merat S; Sharafkhah M; Malekzadeh R; Hekmatdoost A
    Br J Nutr; 2017 Mar; 117(5):662-668. PubMed ID: 28345499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice.
    Onoyama T; Koda M; Okamoto T; Kishina M; Matono T; Sugihara T; Murawaki Y
    Mol Med Rep; 2015 Nov; 12(5):6895-902. PubMed ID: 26397061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats.
    Akaslan SB; Degertekin CK; Yilmaz G; Cakir N; Arslan M; Toruner FB
    Metab Syndr Relat Disord; 2013 Aug; 11(4):243-50. PubMed ID: 23544853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Synbiotics Supplementation in Lean Patients with Nonalcoholic Fatty Liver Disease: Study Protocol of a Pilot Randomized Double-blind Clinical Trial.
    Mofidi F; Yari Z; Poustchi H; Merat S; Nourinayyer B; Malekzadeh R; Hekmatdoost A
    Arch Iran Med; 2016 Apr; 19(4):282-4. PubMed ID: 27041524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of long-term synbiotic supplementation in addition to lifestyle changes in children with obesity-related non-alcoholic fatty liver disease.
    Çakır M; Aksel İşbilen A; Eyüpoğlu İ; Sağ E; Örem A; Mazlum Şen T; Kaklıkkaya N; Kaya G
    Turk J Gastroenterol; 2017 Sep; 28(5):377-383. PubMed ID: 28797988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential involvement of JNK1 repression in the hepatic effect of sitagliptin and metformin in rats subjected to high fat diet and chronic mild distress.
    Magdy YM; El-Kharashi OA; Nabih ES; Shaker SM; Abd-Elaziz LF; Aboul-Fotouh S
    Biomed Pharmacother; 2017 Jan; 85():225-238. PubMed ID: 27916420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials.
    Sáez-Lara MJ; Robles-Sanchez C; Ruiz-Ojeda FJ; Plaza-Diaz J; Gil A
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27304953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bile acids and butyrate in the effects of probiotics/synbiotics on nonalcoholic fatty liver disease.
    Chen J; Vitetta L
    Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1475-1476. PubMed ID: 31464781
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of a Lactobacillus paracasei B21060 based synbiotic on steatosis, insulin signaling and toll-like receptor expression in rats fed a high-fat diet.
    Raso GM; Simeoli R; Iacono A; Santoro A; Amero P; Paciello O; Russo R; D'Agostino G; Di Costanzo M; Canani RB; Calignano A; Meli R
    J Nutr Biochem; 2014 Jan; 25(1):81-90. PubMed ID: 24314869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke (MAAS): study protocol for a randomized controlled trial.
    Osei E; Fonville S; Zandbergen AA; Brouwers PJ; Mulder LJ; Lingsma HF; Dippel DW; Koudstaal PJ; den Hertog HM
    Trials; 2015 Aug; 16():332. PubMed ID: 26242578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathogenetic substantiation of complex treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes].
    Чопей ІВ; Івачевська ВВ; Чубірко КІ; Гряділь ТІ; Гечко ММ
    Wiad Lek; 2017; 70(2):169-173. PubMed ID: 28511152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of mitiglinide and sitagliptin, alone or in combination, on postprandial excursion and glycemic variability assessed by continuous glucose monitoring: a post hoc analysis with single-day treatment.
    Baek JH; Jin SM; Kaku K; Jung JA; Kim JR; Ko JW; Kim MJ; Lee SY; Huh WS; Kim JH
    Expert Opin Pharmacother; 2015 Jun; 16(8):1127-36. PubMed ID: 25881690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking.
    Ramírez E; Picatoste B; González-Bris A; Oteo M; Cruz F; Caro-Vadillo A; Egido J; Tuñón J; Morcillo MA; Lorenzo Ó
    Cardiovasc Diabetol; 2018 Jan; 17(1):12. PubMed ID: 29325553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synbiotic Lactobacillus acidophilus NCFM and cellobiose does not affect human gut bacterial diversity but increases abundance of lactobacilli, bifidobacteria and branched-chain fatty acids: a randomized, double-blinded cross-over trial.
    van Zanten GC; Krych L; Röytiö H; Forssten S; Lahtinen SJ; Abu Al-Soud W; Sørensen S; Svensson B; Jespersen L; Jakobsen M
    FEMS Microbiol Ecol; 2014 Oct; 90(1):225-36. PubMed ID: 25098489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of dextromethorphan as add-on to sitagliptin on blood glucose and serum insulin concentrations in individuals with type 2 diabetes mellitus: a randomized, placebo-controlled, double-blinded, multiple crossover, single-dose clinical trial.
    Marquard J; Stirban A; Schliess F; Sievers F; Welters A; Otter S; Fischer A; Wnendt S; Meissner T; Heise T; Lammert E
    Diabetes Obes Metab; 2016 Jan; 18(1):100-3. PubMed ID: 26362564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Sitagliptin With Closed-Loop Technology to Decrease Postprandial Blood Glucose in Type 1 Diabetes.
    Underland LJ; Ilkowitz JT; Katikaneni R; Dowd A; Heptulla RA
    J Diabetes Sci Technol; 2017 May; 11(3):602-610. PubMed ID: 28349708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of β-cell function ameliorated glycemic variability in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion or in combination with sitagliptin treatment: a randomized control trial.
    Yuan G; Hu H; Wang S; Yang Q; Yu S; Sun W; Qian W; Mao C; Zhou L; Chen D; Wang Z; Gong Q; Wang D
    Endocr J; 2015; 62(9):817-34. PubMed ID: 26194272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease.
    El-Haggar SM; Mostafa TM
    Hepatol Int; 2015 Jul; 9(3):471-9. PubMed ID: 25956613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.